A Trial of HRS-5965 Tablets in Primary IgA Nephropathy

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

123

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

August 31, 2025

Conditions

Primary IgA Nephropathy

Interventions

DRUG

HRS-5965

DRUG

Placebo

Placebo.

Trial Locations (1)

Beijing University First Hospital, Beijing

All Listed Sponsors

lead

Chengdu Suncadia Medicine Co., Ltd.

INDUSTRY

NCT06137768 - A Trial of HRS-5965 Tablets in Primary IgA Nephropathy | Biotech Hunter | Biotech Hunter